Serum uric acid and cardio-renal diseases

References

• Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002;13:2888-97
   PubMed Web of Science ®Google Scholar
• Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol 2000;10:403-9
   PubMedGoogle Scholar
• Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricaemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004;44:642-50
   PubMed Web of Science ®Google Scholar
• Obermayr RP, Temml C, Gutjahr G, et al. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008;19:2407-13
   PubMed Web of Science ®Google Scholar
• Weiss TE, Segaloff A, Moore C. Gout and diabetes. Metabolism 1957;6:103
   PubMed Web of Science ®Google Scholar
• Kinsey D, Walther R, Sise HS, et al. Incidence of hyperuricemia in 400 hypertensive patients. Circulation 1961;24:972
   Google Scholar
• Cannon PJ, Stason WB, Demartini FE, et al. Hyperuricemia in primary and renal hypertension. N Eng J Med 1966;275:457-64
   PubMed Web of Science ®Google Scholar
• Klein R, Klein BE, Cornoni JC, et al. Serum uric acid. Its relationships to coronary heart disease risk factors and cardiovascular disease, Evans County, Georgia. Arch Intern Med 1973;132:401-10
   PubMed Web of Science ®Google Scholar
• Messerli FH, Frohlich ED, Dreslinski GR, et al. Serum uric acid in essential hypertension an indicator of renal vascular involvement. Ann Intern Med 1980;93:817-21
   PubMed Web of Science ®Google Scholar
• Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999;17:869-72
   PubMed Web of Science ®Google Scholar
• Mazza A, Pessina AC, Pavei A, et al. Predictors of stroke mortality in elderly people from the general population. Eur J Epidemiol 2001;17:1097-104
   PubMed Web of Science ®Google Scholar
• Alderman MH, Cohen H, Madhavan S, et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999;34:144-50
   PubMed Web of Science ®Google Scholar
• Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000;18:1149-54
   PubMed Web of Science ®Google Scholar
• Richette P, Bardin T. Gout. Lancet 2010;375:318-28
   PubMed Web of Science ®Google Scholar
• Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 2012;125:679-87
   PubMed Web of Science ®Google Scholar
• Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure independent mechanism. Am J Physiol Renal Physiol 2002;282:F991-7
   PubMed Web of Science ®Google Scholar
• Mazzali M, Hughes J, Kim YG, et al. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001;38:1101-6
   PubMed Web of Science ®Google Scholar
• Khosla UM, Zharikov S, Finch JL. Hyperuricemia induces endothelial dysfunction. Kidney Int 2005;67:1739-42
   PubMed Web of Science ®Google Scholar
• Sánchez-Lozada LG, Tapia E, Santamaría J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237-47
   PubMed Web of Science ®Google Scholar
• Corry DB, Eslami P, Yamamoto K, et al. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J Hypertens 2008;26:269-75
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005;45:18-20
   PubMed Web of Science ®Google Scholar
• Sánchez-Lozada LG, Tapia E, Bautista-Garcia P, et al. Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2008;294:F710-18
   PubMed Web of Science ®Google Scholar
• Nakanishi N, Okamoto M, Yoshida H, et al. Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 2003;18:523-30
   PubMed Web of Science ®Google Scholar
• Masuo K, Kawaguchi H, Mikami H, et al. Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension 2003;42:474-80
   PubMed Web of Science ®Google Scholar
• Sundström J, Sullivan L, D’Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005;45:28-33
   PubMed Web of Science ®Google Scholar
• Perlstein TS, Gumieniak O, Williams GH, et al. Uric acid and the development of hypertension: the Normative Aging Study. Hypertension 2006;48:1031-6
   PubMed Web of Science ®Google Scholar
• Zhang W, Sun K, Yang Y, et al. Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin Chem 2009;55:2026-34
   PubMed Web of Science ®Google Scholar
• Viazzi F, Parodi D, Leoncini G, et al. Serum uric acid and target organ damage in primary hypertension. Hypertension 2005;45:991-6
   PubMed Web of Science ®Google Scholar
• Choi HK, Soriano LC, Zhang Y, et al. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case–control study. BMJ 2012;344:d8190
   PubMed Web of Science ®Google Scholar
• Høieggen A, Alderman MH, Kjeldsen SE, et al; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004;65:1041-9
   PubMed Web of Science ®Google Scholar
• Grayson PC, Kim SY, LaValley M, et al. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:102-10
   PubMed Web of Science ®Google Scholar
• Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008;300:924-32
   PubMed Web of Science ®Google Scholar
• Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 2012;60:1148-56
   PubMed Web of Science ®Google Scholar
• Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2012: published online 20 August 2012, doi:10.1111/j.1751-7176.2012.00701.x
   Google Scholar
• Ishani A, Grandits GA, Grimm RH, et al. Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of endstage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 2006;17:1444-52
   PubMed Web of Science ®Google Scholar
• Conchol MB, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007;50:239-47
   PubMed Web of Science ®Google Scholar
• Viazzi F, Leoncini G, Vercelli M, et al. Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: the MAGIC study. Diabetes Care 2011;34:126-8
   PubMed Web of Science ®Google Scholar
• Sonoda H, Takase H, Dohi Y, et al. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol 2011
   Google Scholar
• Zoppini G, Targher G, Chonchol M, et al. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care 2012;35:99-104
   PubMed Web of Science ®Google Scholar
• Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007;3:443-9
   PubMedGoogle Scholar
• Yu K-H, Kuo C-F, Luo S-F, et al. Risk of end-stage renal disease associated with gout: a nationwide population study. Arthritis Res Ther 2012;14:R83
   PubMedGoogle Scholar
• Siu YP, Leung KT, Tong MK, et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006;47:51-9
   PubMed Web of Science ®Google Scholar
• Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. Int Urol Nephrol 2007;39:1227-33
   PubMed Web of Science ®Google Scholar
• Whelton A, Macdonald PA, Zhao L, et al. Renal function in gout: long-term treatment effects of febuxostat. J Clin Rheumatol 2011;17:7-13
   PubMed Web of Science ®Google Scholar
• Krishnamurthy A, Lazaro DM, Blumenthal DR, et al. The effect of allopurinol on renal function in patients with hyperuricemia: a case–control study. Arthritis Rheum 2010;62:S68-161
   Google Scholar
• Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-93
   PubMed Web of Science ®Google Scholar
• Talaat KM, el-Sheikh AR. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease. Am J Nephrol 2007;27:435-40
   PubMed Web of Science ®Google Scholar
• Nouri-Majalan N, Ardakani EF, Forouzannia K, et al. Effects of allopurinol and vitamin E on renal function in patients with cardiac coronary artery bypass grafts. Vasc Health Risk Manag 2009;5:489-94
   PubMedGoogle Scholar
• Jun M, Venkataraman V, Razavian M, et al. Is antioxidant therapy beneficial for people with chronic kidney disease? The Cochrane Library 2012: published online 17 October 2012, doi:10.1002/14651858.CD008176.pub2
   Google Scholar
• Sánchez-Lozada LG, Tapia E, Santamaría J, et al. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005;67:237-47
   PubMed Web of Science ®Google Scholar
• Kang DH, Park SK, Lee IK, et al. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005;16:3553-62
   PubMed Web of Science ®Google Scholar
• Webb R, Jeffries M, Sawalha AH. Uric acid directly promotes human T-cell activation. Am J Med Sci 2009;337:23-7
   PubMed Web of Science ®Google Scholar
• Roncal CA, Mu W, Croker B, et al. Effect of elevated serum uric acid on cisplatin-induced acute renal failure. Am J Physiol Renal Physiol 2007;293:F116-22
   Google Scholar
• Sánchez-Lozada LG, Tapia E, Soto V, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol 2008;108:69-78
   Web of Science ®Google Scholar
• Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol 2004;287:R1014-30
   PubMed Web of Science ®Google Scholar
• Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol (Lond) 2004;555:589-606
   Google Scholar